Neuromuscular Disorders

Article	Citations
WMS General Information	64
ENMC Themed Workshop announcement	50
WMS General Information	43
Editorial Board	39
ENMC Mid-Career Mentoring Programme	37
366P Social Vulnerability in Duchenne Muscular Dystrophy: The Impact on Boys and Carrier Mothers	35
156P Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma in clinically silent and childhood-onset SMA individuals from Serbia	34
355P A comprehensive education and training programme for healthcare professionals in care and research for Duchenne muscular dystrophy developed from DMD Care UK and the DMD Hub	32
624P A new double-trouble phenotype: fascioscapulohumeral muscular dystrophy and familial amyotrophic lateral sclerosis.	31
81P Minimal clinically important differences in dysferlinopathy from the 10-year, multicenter Jain Clinical Outcome Study	28
326P Acute adverse events after Zoledronic acid infusion are uncommon in patients with Duchenne muscular dystrophy previously treated with oral bisphosphonates	27
279P Exploring myogenic tremor in an animal model of MYBPC1-associated myopathy: a comprehensive study	25
95P Development of a myotropic gene therapy towards a first treatment for LGMDR7	24
WMS 2024 Full Programme	22
365P Duchenne video assessment 2.0 scorecard performance: evaluation of inter-item and inter-scorecard relationships	22
203P Towards a better analysis of SMN2 structures and variants by complete sequencing of the SMN locus in an international cohort of 564 SMA patients	21
389P Natural history of bone health in Duchenne muscular dystrophy: A systematic review and implications for the design of a clinical trial	21
17O Schwann cell transduction and PMP22 target engagement in non-human primates supports translation of RNAi-based gene therapy for CMT1A	21
46P Congenital myopathies and muscular dystrophies in the UK: a comprehensive next generation sequencing analysis of frequencies over an 8-year period (2016-2023)	21
271P Exploring the effects of the epi-drug Remodelin on murine myoblasts differentiation	20
10O The neonatal screening of SMA in Ukraine: the 18 months of experience	20
686P Identification and characterization of actionable deep intron 8 IGHMBP2 hotspot pathogenic variants through motor neuron RNAseq and whole genome	20
INV09 Novel repeat disorders in muscle disease: the emergence of OPDM	19
209P Custom orthosis improves mobility and caregiver experience in an adolescent with congenital myasthenic syndrome and myofibrillar myopathy	19
534P Clinical and genetic characterization of Brazilian patients with TK2 deficiency	19

Diagnostic delay in patients with FKRP-related muscular dystrophy	18
Idiopathic eosinophilic myositis: a systematic literature review	18
Serum miRNAs as biomarkers for the rare types of muscular dystrophy	18
Main features and disease outcome of congenital myotonic dystrophy - experience from a single tertiary center	17
P.174 TRIM32 related muscular dystrophy mimicking inflammatory myopathy: Clinical and histopathological features in two siblings	16
P295 Functional improvements by ataluren in dysferlinopathy mice with a compound heterozygous mutations carrying one nonsense variant	16
P251 Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in novel bmx model mice	15
P.77 Clinical presentation of two Korean patients with adolescent-onset very-long-chain acyl-CoA dehydrogenase deficiency	15
P154 The generation of a GNE myopathy patient-derived biobank enables the study of disease-relevant cellular phenotypes across multiple pathogenic variants	15
A very late onset AChR and MuSK double positive myasthenia gravis: a case description and literature review	15
P311 Facioscapulohumeral muscular dystrophy European patient survey: assessing patient preferences in clinical trial participation	14
Whole-body muscle MRI in McArdle disease	14
P.53 Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients	14
P61 High dose localized muscle irradiation: Hedgehog pathway as a new therapeutic target	14
P.144a Muscle ultrasound in an open-label study of losmapimod in subjects with FSHD1	14
P137 Prophylactic use of cardiac medications and prolonged survival in Duchenne muscular dystrophy	14
P.30 Correlation of histopathological skeletal muscle biopsy features with quantitative muscle-MRI parameters	14
P.135 Safety and tolerability of losmapimod for the treatment of FSHD	13
P443 A case of Charcot-Marie-Tooth Type 4F	13
P.224 Non-5q spinal muscular atrophy in twin sisters with SPG11/CMT2X associated spatacsin gene mutation	13
P33 RKER-065 ameliorated muscle and bone loss in a progressive murine model of Duchenne muscular dystrophy	13
VP.28 Psychometric properties of muscle strength assessment by hand-held dynamometry in healthy adults: A reliability study	13
P164 Development of a myotube model for C-terminal titin studies	12
Raised CK and acute kidney injury following intense exercise in three patients with a history of exercise intolerance due to homozygous mutations in SLC2A9	12
P145 Analysis of the natural evolution of SV95C in ambulant patients with Duchenne muscular dystrophy	12
Emerging and established biomarkers of oculopharyngeal muscular dystrophy	11
15PPrimary skeletal muscle peripheral T-cell lymphoma associated with HIV presenting with myopathic symptoms	11
674PDelpacibart zotadirsen (del-zota) increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44	11
P.17 Importance of routine pulmonary check-up prior to ventilatory support in patients with Duchenne muscular dystrophy	11
191PComprehensive analysis of longitudinal SV95C measurements, an e-digital mobility assessment in a real-life DMD population in the GNT-014-MDYF natural history study	11
P304 JOURNEY: a multicenter, longitudinal natural history study of limb girdle muscular dystrophy	11
Collagen VI-related myopathies: clinical variability, phenotype-genotype correlation and exploratory transcriptome study	11
409PDouble-blind, placebo-controlled study assessing effects of tranilast on motor, respiratory, and cardiac functions in Duchenne muscular dystrophy	11
639PFunctional ability and quality of life in Duchenne muscular dystrophy	10
594PEvaluating oxygen saturation and recovery dynamics in skeletal muscle during exercise in adults with spinal muscular atrophy	10
312PClinical and muscle MRI findings of Bethlem myopathy: case series	10
35PThe impact of idiopathic inflammatory myopathy on quality of life: data from a tertiary healthcare in Indonesia	10
138PMuscle imaging of the patients with RYR1-related myopathies and its significance to clinical features	10
122PSporadic late-onset nemaline myopathy with monoclonal gammapathy of unknown significance treated with melphalan and autologous hematopoietic stem cell transplantation	10
276PQuantitative measurement of near full-length dystrophin and muscle content normalizer proteins in human muscle by IA-UPLC-MS/MS	10
144PXLMTM female carriers: a review of patient reported data collected by the MTM & CNM patient registry	10
192P A community-based experience with the new 12-Tier functional ability scale for Evolving Spinal Muscular Atrophy (EVOLVE-SMA)	9
231PSystemic deletion of Gne in adult mice results in thrombocytopenia, anemia, spontaneous bleeding, myopathy and premature death	9
443PAcute respiratory failure in pregnancy: the presenting symptom of a disorder of gliomedin, an essential component of the nodes of Ranvier	9
The experience of clinical study and trial participation in rare diseases: A scoping review of centronuclear myopathy and other neuromuscular disorders	9
UPDATE IN NEUROMUSCULAR DISORDERS	9
22O Mexiletine versus lamotrigine in non-dystrophic myotonias – a randomised, double-blinded, cross-over trial	9
628PUnraveling a veil: a rare genetic aberration causing muscular dystrophy in a female	9
608PScoliosis development in SMA patients treated with nusinersen: a single-center experience	9
562PDanon disease in Japan: a nationwide additional analysis	9

329P Siblings with Duchenne muscular dystrophy: a chart review to explore associations between age of diagnosis and clinical disease outcomes	9
253rd ENMC international workshop: Striated muscle laminopathies - natural history and clinical trial readiness. 24–26 June 2022, Hoofddorp, the Netherlands	9
289PNatural history study of the D2-mdx mouse for Duchenne muscular dystrophy: a comparison across two independent study sites	9
67PMexiletine Paediatric Investigation Plan, PIP4 study: safety, pharmacokinetic and efficacy findings in children with myotonia	9
Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls	9
155P The experience of parents as they make treatment decisions for their child with spinal muscular atrophy and the factors that influence these decisions: a narrative review	8
270PIndividuals with Duchenne muscular dystrophy have lower brain volumes, altered white matter microstructure and lower perfusion compared to controls	8
587P White matter lesions and genetic muscular diseases: an overview	8
531P The French registry of glycogen storage disease type 3	8
225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skipping	8
ENMC Themed Workshop announcement	8
The relationship between patient-reported and clinician-assessed outcome measures in Inclusion body myositis - insights from a retrospective cohort study	8
403P CONNECT1-EDO51: a 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping	8
218PPhenotype-genotype heterogeneity of multisystemic myopathies – a study from India	8
496P Recessive missense variants in DARS2 gene as novel cause of axonal Charcot-Marie-Tooth disease	8
480PComparison of children with myasthenia gravis and congenital myasthenic syndrome: a case series	8
462P Evaluating EEG as an outcome measure for CNS Symptoms in myotonic dystrophy type 1: a clinical trial analysis	8
80P Evaluating the clinical significance of single heterozygous likely pathogenic and pathogenic variants for autosomal recessive limb-girdle muscular dystrophies in a highly specialised service for r	8
139P Treatment effects on ambulation loss in Spinal Muscular Atrophy Type III: insights from the Italian ISMAC registry	8
581P Toxic autophagic vacuolar myopathies and the role of human leukocyte antigen class I molecules and membrane attack complex in its pathogenesis	8
ENMC Themed Workshop announcement	8
Comments on ‘Life-threatening bowel complications in adults with Duchenne muscular dystrophy: a case series’	8
Evaluation of dynamin 2 knockdown as a therapeutic strategy for RYR1 related myopathy	8
430VPCare of dystrophinopathy carriers: survey results of provider practices in the U.S.	8
597VP Vacuolar myopathy with permanent weakness: case report with imaging, muscle biopsy, and molecular features	8
505VP Safety and effectiveness of ravulizumab in gMG: evidence from a global registry	8
287P3D tissue engineered skeletal muscle to model dystrophinopathies and determine the efficacy of exon skip therapies	8
523P Rare disease register: McArdle disease and glycogenoses	8
I.07 Clinical trial readiness across the lifespan in Charcot-Marie-Tooth disease	7
P194 The Duchenne registry: key milestones and advances of a patient-report registry	7
Novel association of gluten sensitivity with immune-mediated neuromuscular syndrome in a dog	7
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study	7
75PJM17, a novel curcumin analog modulates mitochondrial, inflammatory, and fibrotic pathways in the muscle of a transgenic SBMA mouse: transcriptomic insights beyond NRF2 activation	7
145PLycra foundation suit intervention in patients with RYR1-related congenital myopathy: a case study of functional improvement	7
580POrganizational, economic and environmental impacts of oral and intrathecal administrations for spinal muscular atrophy treatments in France	7
VP.21 Baseline nutrition investigation in a Chinese cohort of pediatric patients with spinal muscular atrophy	7
P.43 Evaluating knee ankle foot orthoses in children with type 1 spinal muscular atrophy	7
WMS General Information	7
P412 Expanding the clinical and genetic spectrum of biallelic pathogenic MYO18B variants in congenital myopathy	7
555PMultisystem involvement in oculopharyngodistal myopathy: insights into cardiac manifestations and genotype-phenotype correlations	7
346PExploring the natural history of late-onset TK2 deficiency: biomarkers and key outcomes	7
298PAnalysis of long-term clinical and MRI findings highlights progressive nature of Ano5-related myopathies and the role of imaging as a valuable outcome measure	7
01O Interferon-γ causes myogenic cell dysfunction and senescence in immune myopathies	7
P.145 Identification of potential genetic modifiers underlying phenotypic variability in a French family with striated muscle laminopathies	7
P.193 Phosphoryl guanidine-containing backbone modifications enhance exon skipping, dystrophin restoration and survival in a severe mouse model for DMD	7
Obituary: Professor Annie Barois (1930-2024)	7
10OSexual and pelvic floor function in women with muscular dystrophy	7
18PGuillain-Barré syndrome in children: insights from a 20-year retrospective cohort study at a tertiary referral center	7
635PFat fraction of the myocardium in Becker muscular dystrophy and women with patho-genic DMD gene variants	7
P392 Assessing the cognitive effect of methylphenidate treatment in childhood myotonic dystrophy type 1 and comorbid attention deficit hyperactivity disorder using eye tracking: a case report	6
WMS 2022 Flyer	6
P262 Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne muscular dystrophy	6
Antisense oligonucleotide-mediated redirection of Igf1 alternative polyadenylation	6
A homozygous loss of function variant in POPDC3: From invalidating exercise intolerance to a limb-girdle muscular dystrophy phenotype	6
Clinical potential of microdystrophin as a surrogate endpoint	6
P112 ‘Going when you have to’ – a national survey on problems in urinating when away from home for women with NMD - Project HAP-PEE part 2	6
Editorial Board	6
P134 Energetics and acid-base status of skeletal muscle at rest and following isometric dorsiflexion and plantar flexion contractions in Duchenne muscular dystrophy	6
P418 Dominant cardioskeletal titinopathies reflect distinct mechanisms of disease	6
P.144 Developing Cas13-ADAR-mediated DUX4 mRNA editing as a prospective therapy for FSHD	6
VP.73 Characteristics of cardiac dysfunction in patients with Fukuyama congenital muscular dystrophy	6
P109 The effect of a two-week intensive and individualized physiotherapy intervention for patients with rare genetic neuromuscular disorders: a quality improvement study	6
267th ENMC International workshop: psychological interventions for improving quality of life in slowly progressive neuromuscular disorders	6
Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis	6
Suitability of the Respicheck questionnaire and Epworth sleepiness scale for therapy monitoring in myotonic dystrophy type 1	6
P346 Late and very late onset of McArdles’ myopathy without myoglobinuria	6
O21 104-week efficacy and safety of cipaglucosidase alfa+miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa	6
INV02 High throughput functional assays to improve interpretation of rare variants discovered in neuromuscular disease genes	6
P.214 Utility of ENMG in children with rare genetic neurogenic disorders: a case series	6
P.204 Blood based biomarker discovery in DM1	6
Characterization of neuromuscular performances in adults with late-onset Pompe disease: A control case cross-sectional study	6
INV11 Motor neuron and muscle involvement in SBMA: therapeutic implications	6
TNNT1 myopathy with novel compound heterozygous mutations	6
Defining the landscape of TIA1 and SQSTM1 digenic myopathy	6
P50 A phase 1/2 randomized, placebo-controlled, multiple ascending dose study (ACHIEVE) of DYNE-101 in individuals with myotonic dystrophy type 1 (DM1)	6
Editorial Board	6
O18 Topline safety and efficacy data analysis of phase 1/2 clinical trial evaluating AOC 1001 in adults with myotonic dystrophy type 1: MARINA TM	6
P09 Real-world treatment with risdiplam in adults with spinal muscular atrophy (SMA): a multicenter study	6
526P Clinical spectrum and treatment in paediatric TANGO2 deficiency disorder	5
Table of Contents for the Main Abstracts	5

09O The clinical and molecular landscape of genetic neuromuscular disorders in Senegal, West Africa	5
Two tales of LPIN1 deficiency: from fatal rhabdomyolysis to favorable outcome of acute compartment syndrome	5
584PVascular perfusion abnormalities in an infant with spinal muscular atrophy type 0	5
125P A review of the management and outcomes of children with SMA in the West Midlands, UK during 2017-2022	5
71PSafety of pyrimidine nucleos(t)ide therapy in Thymidine kinase 2 deficiency: an integrated analysis from a pooled dataset	5
671P Miglustat: a first-in-class enzyme stabiliser for late-onset Pompe disease	5
620PFamily caregivers’ administrative burden for persons with Duchenne’s muscular dystrophy: a reflection of all stakeholders	5
204P A phase 1 study of antisense oligonucleotide NS-035 in patients with Fukuyama congenital muscular dystrophy	5
583PAdd-on treatment with risdiplam after treatment with onasemnogene abeparvovec: case report of a 2.5-year-old patient with SMA type 1	5
517PAdult SMA REACH: characterisation of adult patients living with spinal muscular atrophy at start of treatment in the UK	5
524PLong-term use of disease-modifying therapies in spinal muscular atrophy – a population based study	5
Quality of life in hypokalemic periodic paralysis - a survey	5
452P Genetic confirmation of myotonic dystrophy type II after allogeneic stem cell transplant	5
648P MRI demonstrates altered skeletal muscle membrane permeability in Becker muscular dystrophy, representing a potential biomarker for disease activity	5
Granulomatous myositis: characteristics and outcome from a monocentric retrospective cohort study	5
200P Minimal detectable change of the Revised Hammersmith Scale in patients with spinal muscular atrophy	5
162PInteraction studies of the titin A150 domain in C2C12 myotubes	5
572P Dysphagia pattern in inclusion body myositis as a distinguishing feature: insight from a patient initially presenting with rapidly progressing dysphagia	5
341PExposure to sertraline and ranolazine is common among adult patients with genetically uncharacterized lipid storage myopathy	5
586P Visualization of degenerative processes of the myofibers on muscle pathology in OPDM based on single nucleus RNA-seq data	5
217PDirect and indirect socio-economic burden of facioscapulohumeral muscular dystrophy (FSHD): a national, cross-sectional study	5
27P Muscle ultrasound findings in paediatric patients with TTN gene related congenital myopathy	5
641PA cross-sectional comparison of ambulatory versus non-ambulatory patients with Duchenne muscular dystrophy (DMD) at 16 years of age	5
278PFlash electroretinogram alterations in the absence of distinct retinal dystrophins in different mouse models of Duchenne muscular dystrophy	5
ENMC Themed Call 2023-2024 Announcement	5
Guide for location of abstracts	5
222P Development of a standardized information model for rare neuromuscular diseases	5
25P Data trends and highlights from The Global Registry for COL6-related dystrophies	5
279PCardiac affection in women carrying pathogenic variants in the dystrophin gene: a 7-year follow-up study	5
Clinical and genetic characteristics based on the Japanese patient registry for facioscapulohumeral muscular dystrophy: a nationwide analysis	5
657P Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa	5
371PInvestigating hand myotonia: determining best practices using novel technologies and approaches to assessing hand myotonia	5
636P Longitudinal insights into childhood onset facioscapulohumeral dystrophy: a five-year natural history study	5
388PNeurofilament light chain correlates with the motor function scales in myotonic dystrophy type 1	5
634P Retrospective analysis of muscle biopsy findings in a cohort of patients with facioscapulohumeral dystrophy type 1	5
146PClinical, molecular, and pathological characterization of MYL1-related congenital myopathy: report of two novel cases	5
693P Proposed NIH core for advanced genetic therapies: spotlight on clinical development of AAV products for neuromuscular disorders	5
353PUnexpected attenuated phenotype in autosomal recessive progressive external ophthalmoplegia linked to a novel homozygous pathogenic RRM2B gene variant	5
687VPModeling disease progression in Duchenne muscular dystrophy: reduced decline in forced vital capacity with givinostat compared with standard of care	5
P323 Differences in clinicopathology and therapeutic response of idiopathic inflammatory myopathy with anti-SRP, HMGCR, and mitochondrial M2 antibodies	4
Neuropsychological and behavioral profile in a cohort of Becker muscular dystrophy pediatric patients	4
P51 Phase 1/2 study to evaluate AOC 1020 for adult patients with facioscapulohumeral muscular dystrophy: FORTITUDE trial design	4
13INV AAV delivery of mini- and full-length dystrophins	4
P.40 The importance of bulbar/respiratory symptoms in spinal muscular atrophy: results from interviews with patients, caregivers and healthcare providers	4
A genetic basis is identified in 74% cases of paediatric hyperCKaemia without weakness presenting to a tertiary paediatric neuromuscular centre	4
604P Descriptive analysis of Duchenne muscular dystrophy patients included in the Swedish National Registry for neuromuscular disorders	4
487P 2024 update of the national French consensus on gene lists for the diagnosis of muscular diseases using high-throughput sequencing	4
66P Clinical and molecular complexity in desminopathy: description of a novel variant in DES gene	4
Digital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite	4
524P Grip strength in McArdle disease	4
VP.46 Dermatomyositis-specific autoantibodies and muscle MRI findings	4
P.38 A novel splice site variant in a patient with spinal muscular atrophy and hypoplastic left heart syndrome	4
P22 WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses	4
P234 Effect of Apitegromab on pedi-cat and promis-fatigue questionnaire at 36-months in patients with spinal muscular atrophy	4
P285 Bi-allelic variants in HMGCR cause limb girdle muscular dystrophy and further implicate the mevalonate pathway in muscle disease	4
Prediction of respiratory impairment in myotonic dystrophies using the ‘Respiratory involvement symptom checklist’ (Respicheck)	4
P.134a Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update	4
Neuropathic pain	4
557P Skin manifestations of immune-mediated necrotizing myopathy with anti-HMGCR antibody	4
Editorial Board	4
258P Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old: phase 4 OFELIA study	4
Contents	4
P.111 Nusinersen in children and adults with spinal muscular atrophy in Argentina: Real world experienc	4
Clinical profile and multidisciplinary needs of patients with neuromuscular disorders transitioning from paediatric to adult care	4
O03 In vivo gene therapy for striated muscle laminopathy	4
VP71 Exploring the construct validity and reliability of sensor-based measurements derived from active motor assessments in adult walkers with SMA	4
P223 Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy (SMA) type 1	4
Muscle Biopsy A Practical Approach 5th Edition	4
VP.88 Characterisation of cell culture models of myotonic dystrophy type I by In-Cell Western technology and digital droplet PCR	4
INV04 Accounting for phenotypic variability in clinical outcomes	4
677P The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1	4
317VP Overview of a cohort of 35 manifesting dystrophinopathy females – and addressing the forthcoming challenges	4
566P ClC-1 chloride channel inhibition improves disease symptoms and survival in a rat model of muscle-specific kinase (MuSK) myasthenia gravis	4
590P Genetic heterogeneity in PLIN4 gene: characterization of a new pathogenic expansion causing an autophagic vacuolar myopathy	4
275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9–11 February 2024, Hoofddorp, the Netherlands	4
VP.29 Safety analysis of home-based enzyme replacement therapy with alglucosidase alfa in Pompe disease; a prospective study	4
P124 A series of dysferlinopathy patients showing fluctuations in muscle fat fraction and contractile cross-sectional area values (cCSA) over a 3-year follow-up period	4
574PMobile health technology in late-onset Pompe disease: short-term follow-up after switching to avalglucosidase alpha	3
571P Muscular metabolic plasticity in 3D in vitro models against systemic stress factors in ME/CFS and long COVID-19	3
566POptimization of in vitro models’ generation to unveil the molecular pathomechanisms underlying PLIN4-related myopathy	3
650VPNeuropsychiatric assessment in adults with Duchenne muscular dystrophy	3
33P Description of natural history baseline characteristics of a paediatric cohort of recessive TTN myopathy patients in the UK – a prospective study	3
468PDecoding disease, designing therapies: the B2B-RARE precision medicine initiative for hereditary neuromuscular diseases	3
152PFrom data scarcity to diagnostic accuracy: artificial intelligence approaches in collagen VI muscular dystrophy	3
623PDMD missense variants in the ZZ domain cause severe dystrophinopathy despite the co-expression of dystrophin and utrophin at the sarcolemma	3
475PHigher risk of fractures in myasthenia gravis patients in comparison with general population – national healthcare database study	3
330PCardiovascular risk factors and atheromatosis in spinobulbar muscular atrophy (SBMA) Kennedy in association with lipid and hormone profile	3
157PCell painting for the study of SELENON-congenital myopathy cell models	3
697P Clinicians' perspectives on a new self-management support programme for people living with neuromuscular disorders	3
554P Mitochondrial pathology in myositis: a multicentric case series	3
Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH)	3
615PLiver injury after gene therapy in Duchenne muscular dystrophy: a case report and clinical perspective on screening and management	3
Editorial Board	3
Recommendations of an expert group for the cardiac assessment of non-dystrophic myotonia adult patients treated with mexiletine	3
183PThe impact of genotype on north star ambulatory assessment in individuals with Duchenne muscular dystrophy treated with corticosteroids: a single-center study of 416 patients	3